Alex F Herrera

Trials

Studies that name Alex F Herrera as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:55 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT04871607 · Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

  City of Hope Medical Center · recruiting · Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma · principal investigator
• Ph2
  NCT04665765 · Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  City of Hope Medical Center · active not recruiting · Diffuse Large B-Cell Lymphoma Unclassifiable, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma · principal investigator
• Ph2
  NCT04561206 · Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

  City of Hope Medical Center · recruiting · Relapsed Classic Hodgkin Lymphoma · principal investigator
• Ph3
  NCT03907488 · Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

  National Cancer Institute (NCI) · active not recruiting · Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma · principal investigator
• Ph2
  NCT03712202 · Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

  City of Hope Medical Center · active not recruiting · Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma · principal investigator
• Ph1/Ph2
  NCT03598998 · Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

  City of Hope Medical Center · active not recruiting · Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma · principal investigator
• Ph1
  NCT03321643 · Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

  National Cancer Institute (NCI) · active not recruiting · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma · principal investigator
• Ph1
  NCT03150329 · Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

  City of Hope Medical Center · active not recruiting · Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL, Recurrent Classic Hodgkin Lymphoma · principal investigator
• Ph2
  NCT03113500 · Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

  City of Hope Medical Center · active not recruiting · Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive · principal investigator
• Ph2
  NCT03016871 · Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

  City of Hope Medical Center · active not recruiting · Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma · principal investigator
• Ph1
  NCT03013933 · Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

  City of Hope Medical Center · completed · Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 01:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Clinical Protocol and Data Management
  P30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2026 · $222,906 awarded in 2026
  Grant number is on one of their registry trials
• Leading NCI Clinical Trials Network research nationally and at the City of Hope Comprehensive Cancer Center
  R50CA285409 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2024 to 2026 · $208,103 awarded in 2026
  Same name and institution; not confirmed by an ID
• Targeted immunotherapy for relapsed/refractory Hodgkin lymphoma
  P50CA107399 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · fiscal years 2018 · $336,786 awarded in 2018
  Grant number is on one of their registry trials

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• SWOG Network Group Operations Center of the NCTN
  U10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026
  Named on NCT03907488
• Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN
  UM1CA186717 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI A. Dimitrios Colevas, Alexey V. Danilov, PRIMO N. LARA, HEINZ JOSEF LENZ · fiscal years 2014 to 2026
  Named on NCT03321643